This review summarises our current understanding of the diverse and complex roles of aberrant Rho/ROCK signalling in tumour development and progression, highlighting new avenues for the utilisation of ROCK inhibitors as anti-cancer therapy, increasingly in the context of modulating the tumour microenvironment. This evidence concerns the gene RHO and neoplasm.